SCHEMBL2646281

SCHEMBL2646281

Cn1nncc1CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31222512 0.82
SCHEMBL2759612 0.78
Hydrochloric Acid SCHEMBL23537951 0.74
SCHEMBL25306113 0.74 PTGS2 (0.39)
SCHEMBL5656543 0.74 GGPS1 (0.36)
SCHEMBL19454798 0.73
SCHEMBL25159807 0.73 SLC1A3 (0.33)
SCHEMBL20953440 0.71 PTGS2 (0.38)
SCHEMBL7697025 0.71
SCHEMBL16815524 0.70 MGMT (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026101971-A2 EGFR INHIBITORS FOR TREATING DISEASE BLOSSOMHILL THERAPEUTICS, INC. (US) 2026-05-15 WO disclosed
US-20260070896-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2026-03-12 US disclosed
US-12404266-B2 Heterocycle derivatives for treating TRPM3 mediated disorders KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-09-02 US disclosed
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-01-28 US disclosed
US-20240336602-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2024-10-10 US disclosed
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-20240051949-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2024-02-15 US disclosed
WO-2024022314-A1 TRIAZOLE COMPOUNDS AND USE THEREOF AS LPAR1 ANTAGONIST 武汉人福创新药物研发中心有限公司 2024-02-01 WO disclosed
EP-4251616-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven (BE) 2023-10-04 EP disclosed
CN-116745283-A Heterocyclic derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2023-09-12 CN disclosed
EP-1121361-B1 PYRAZOLO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2007-08-29 EP disclosed
WO-2004065388-A1 FLUOROIMIDAZOPYRIMIDINES AS GABA-A ALPHA 2/3 LIGANDS FOR DEPRESSION/ANXIETY MERCK SHARP & DOHME LIMITED (GB) 2004-08-05 WO disclosed
EP-0915875-B1 SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2003-04-09 EP disclosed
US-6476030-B1 Pyrazolo-triazine derivatives as ligands for GABA receptors MERCK SHARP & DOHME LTD. 2002-11-05 US disclosed
EP-1121361-A1 PYRAZOLO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS Merck Sharp &amp; Dohme Limited (GB) 2001-08-08 EP disclosed
US-6255305-B1 PSYCHOLOGICAL DISORDERS MERCK SHARP & DOHME LIMITED (GB) 2001-07-03 US disclosed
WO-2000023449-A1 PYRAZOLO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2000-04-27 WO disclosed
CN-1251589-A Substituted triazolopyridazine derivatives as ligands for GABA receptors MERCK SHARP & DOHME (GB) 2000-04-26 CN disclosed
EP-0915875-A2 SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP &amp; DOHME LTD. (GB) 1999-05-19 EP disclosed
WO-1998004559-A2 SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 1998-02-05 WO disclosed